1. Introduction {#s0005}
===============

Stroke, becoming one of the leading causes of morbidity and mortality across the world, brings increasingly great pressure to human lives. The large majority (85%) of strokes are ischemic stroke, that is, a stroke resulting from an occlusion of a major cerebral artery, and commonly it occurs in the middle cerebral artery[@bib1], [@bib2]. Although remarkable advances have been made in understanding the pathophysiology of cerebral ischemia, effective therapies are still a troubling aspect of human. To date, intravenous thrombolysis has been regarded as an effective strategy for the treatment of acute ischemic stroke[@bib3]. However, rapid reperfusion accompanied by a large number of reactive oxygen species (ROS) by thrombolytic therapies, could exacerbate brain injury, namely cerebral ischemia-reperfusion injury (CIRI). Among a series of mechanisms related to the pathogenesis of CIRI, oxidative stress has been considered as the main reason[@bib4], [@bib5]. Oxidative stress, arising from the uncontrolled production of ROS beyond the neutralizing capacity of the various endogenous defense systems, including enzymatic and non-enzymatic matters, leads to cerebral cell apoptosis and neuronal damage[@bib6], [@bib7], [@bib8]. Therefore, exogenous supplementation of antioxidants with ROS scavenging activity would be a potential therapy to cerebral ischemia-reperfusion injury prevention.

Currently, there are two main classes of antioxidants based on the mechanism of inhibiting ROS: (1) compounds that can directly react with ROS are the so-called direct antioxidants, which have the ability to break down the procession of radical chain reactions, like edaravone, resveratrol, quercitin and so on[@bib9], [@bib10], [@bib11]. (2) Indirect antioxidants are compounds that do not directly react with ROS but are involved in activating cellular endogenous antioxidant signaling pathways and promoting the transcription of a broad range of cytoprotective genes to remove ROS, where KEAP1*/*NRF2*/*ARE is one of the important antioxidative signaling pathways. Many indirect antioxidants, such as TBHQ, curcumin and sulforaphane, that modify cysteine residues in the protein KEAP1, cause the dissociation of NRF2 from the inhibitory partner KEAP1 and facilitate NRF2 to translocate into the nucleus, where NRF2 binds to the antioxidant-responsive element (ARE) consensus sequence to activate the transcription of a panel of cytoprotective genes (phase II genes)[@bib9], [@bib11], [@bib12], [@bib13]. Despite extensive research on these two types of antioxidants, most antioxidants have been unsuccessful for clinically treating stroke except edaravone and other very few antioxidants. Moreover, direct and indirect antioxidants are not particularly effective in treating cerebral ischemia-reperfusion injury, which may be related to its own \"birth defects\". Direct antioxidants are short-lived, which may need to be continually provided to halt the process of cerebral ischemia-reperfusion injury[@bib11]. While stimulation of cellular endogenous antioxidant defense pathways by indirect antioxidants require a certain time, and during the period of time before activating the pathway, there is a risk that the brain would be irreversibly damaged by ROS insult, since indirect antioxidants itself could not remove ROS immediately. Besides, up till now, there have been no reports about \"dual-antioxidant mechanism action\" for antioxidant therapy *via* both directly and indirectly scavenging ROS. Moreover, it is not clear whether antioxidants with dual-antioxidant mechanism may have a better prospect than the ones with mono-antioxidant mechanism for cerebral ischemia-reperfusion injury therapy. Herein, we hypothesized that antioxidant agents with ROS scavenging activity directly and indirectly may be more effective therapeutic strategies for stroke treatment.

Natural products and their synthetic analogues have been shown to be invaluable resources in drug discovery[@bib14], [@bib15], [@bib16]. Chalcones or (*E*)-1,2-diphenyl-2-propene-1-ones, make up a group of natural products that attach to the flavonoid family[@bib17]. They consist in various of flowers, fruits, vegetables, and have been reported to possess many biological properties including antioxidant[@bib18], [@bib19], [@bib20], antibacterial[@bib21], anticancer[@bib22], [@bib23], antiangiogenic[@bib24], and anti-inflammatory activities[@bib25], [@bib26]. Among all the biological activities, the antioxidant activity has been extensively studied. Given that a number of small molecules bearing polyhydroxyl groups exhibit a great efficacy in antioxidant activity due to their potent abilities to scavenge ROS directly[@bib27], [@bib28], [@bib29], [@bib30], and it is well-known that the electrophilic *α*,*β*-unsaturated ketone moiety (Michael acceptor) on a chalcone can result in activation of the NRF2 pathway[@bib31], polyhydroxychalcones thus may be considered as monomers to study the potential of double antioxidative properties. In the study, we reported a number of novel (*E*)-3,4-dihydroxychalcone analogues as anti-ischemic stroke agents that attenuate oxidative stress by directly scavenging ROS and indirectly through KEAP1*/*NRF2*/*ARE pathway activation, leading to massive ROS elimination and subsequent inhibition of the ischemia-reperfusion-related brain injury in animals.

2. Results {#s0010}
==========

2.1. Design and synthesis of chalcone analogues {#s0015}
-----------------------------------------------

Previous studies have demonstrated that chalcone-based compounds are involved in the indirect antioxidant effect *via* activation of the NRF2*/*ARE pathway[@bib31]. Polyphenols are considered as an appropriate structural element for designing direct antioxidant compounds, especially compounds bearing 3,4-dihydroxyl substituents on benzene ring showed potent free radical scavenging effects[@bib32]. Besides, the presence of the *α*,*β*-double bond on chalcone could increase the stabilization of the phenolic radical[@bib32]. Therefore, chalone analogues containing 3,4-dihydroxyl substituents may show effective direct and indirect antioxidant activities. In present study, a series of (*E*)-3,4-dihydroxychalcones and corresponding dimethoxychalcones derivatives as control compounds were synthesized. Furthermore, in order to explore whether 3,4-dihydroxyl substituents in the "A" or "B" ring of chalcones have different effects on antioxidant activity, different moieties were introduced on one benzene ring, while another benzene ring retained the 3,4-dihydroxyl substituents.

The synthetic profiles of the compounds and their chemical structures are listed in [Scheme 1](#f0030){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}. The target chalcone-based compounds were synthesized by the Claisen---Schmidt condensation with NaOH or HCl as catalyst in good yield by a known literature method[@bib33], [@bib34], [@bib35]. In summary, substituents such as halogen, amidogen, methoxyl and ethyoxyl were catalyzed by NaOH, and others such as hydroxyl were catalyzed by HCl. The purity was determined by TLC, and the products were characterized by analysis and comparison of their spectral and physical data including HR-MS, ^1^H NMR and ^13^C NMR. The color, melting point, HR-MS, ^1^H NMR and ^13^C NMR spectrum of novel and unpublished compounds were presented in the chemical section.Scheme 1Synthesis of chalcone derivatives **1**--**41**. Reagents and conditions: EtOH, 40% NaOH or HCl, room temperature, 12--24 h.Scheme 1Table 1The structures of chalcone derivatives **1**--**41**.Table 1Compd.R in A-ringR′ in B-ringCompd.R in A-ringR′ in B-ring**1**3,4-OH3-OH**22**3,4-OCH~3~3,5-F**2**3,4-OCH~3~3-OH**23**4-OCH~3~3,4-OH**3**3,4-OH4-NH~2~**24**4-OCH~3~3,4-OCH~3~**4**3,4-OCH~3~4-NH~2~**25**3-OH, 4-OCH~3~3,4-OH**5**3,4-OH4-OCH~3~**26**3-OH, 4-OCH~3~3,4-OCH~3~**6**3,4-OCH~3~4-OCH~3~**27**2,4-OCH~3~3,4-OH**7**3,4-OH4-OCH~2~CH~3~**28**2,4-OCH~3~3,4-OCH~3~**8**3,4-OCH~3~4-OCH~2~CH~3~**29**2-OCH~3~3,4-OH**9**3,4-OH4-Cl**30**2-OCH~3~3,4-OCH~3~**10**3,4-OCH~3~4-Cl**31**2,3-OCH~3~3,4-OH**11**3,4-OH2-F**32**2,3-OCH~3~3,4-OCH~3~**12**3,4-OCH~3~2-F**33**2,5-OCH~3~3,4-OH**13**3,4-OH2-Cl**34**2,5-OCH~3~3,4-OCH~3~**14**3,4-OCH~3~2-Cl**35**4-Cl3,4-OH**15**3,4-OH4-F**36**4-Cl3,4-OCH~3~**16**3,4-OCH~3~4-F**37**3,4-Cl3,4-OH**17**3,4-OH3,4-F**38**3,4-Cl3,4-OCH~3~**18**3,4-OCH~3~3,4-F**39**3,4,5-OCH~3~3,4-OH**19**3,4-OH3,4-OCH~3~**40**3,4,5-OCH~3~3,4-OCH~3~**20**3,4-OCH~3~3,4-OCH~3~**41**3,4-OCH~3~3,4-OH**21**3,4-OH3,5-F

2.2. Protection of chalcone derivatives from H~2~O~2~-induced damage in PC12 cells {#s0020}
----------------------------------------------------------------------------------

Hydrogen peroxide (H~2~O~2~) as an endogenous cellular signaling molecule could generate exogenous free radicals immediately, which are able to induce lipid peroxidation, and proteins and nucleic acid oxidation, and ultimately lead to cell death[@bib36], [@bib37]. Therefore, we evaluated chalcone analogues as potential cytoprotective agents against H~2~O~2~-mediated cell damage in a neuron-like cell line, PC12 cells.

Pre-incubation with antioxidants for a long time (more than 6 h), the antioxidants could stimulate endogenous antioxidant defense systems against ROS[@bib38], [@bib39]. The cells were pretreated by the tested compounds for 24 h, and then treated with H~2~O~2~ insult could be accepted as an experimental method for studying antioxidant activity[@bib39], [@bib40], [@bib41], [@bib42], [@bib43]. Therefore, to study cytoprotection activity of compounds, the screening model of pre-incubation for 24 h was used in this test first. Quercetin, edaravone (ED) and TBHQ are well-known antioxidants, which are used as the positive controls. As shown in [Fig. 1](#f0005){ref-type="fig"}A, some (*E*)-3,4-dihydroxychalcones exhibited good protective efficacy, while only a few (*E*)-3,4-dimethoxychalcones displayed weak cytoprotection. Surprisingly, among these (*E*)-3,4-dihydroxychalcones, chalcones with 3,4-dihydroxyl groups on ring "A", electron donating groups or electron withdrawing groups on ring "B", all displayed potent cytoprotection. Moreover, compared with quercetin, ED and TBHQ, compounds **23, 25**, **29**, **31**, **33**, **37**, **39** and **41** exerted greater cytoprotection effects. However, only compounds **7**, **13** and **19** bearing 3,4-dihydroxyl substituents on ring "B" had cytoprotection activity.Figure 1Compounds׳ cytoprotection on PC12 cells in H~2~O~2~ damage model and DPPH radical scavenging activities of chalcone analogues. PC12 cells were pretreated for 24 h (A) or 1 h (B) with chalcone analogues (10 μmol/L), then another 24 h exposure in H~2~O~2~ (450 μmol/L), finally determined by the MTT assay. The viability of untreated cells is defined as 100%. (C) DPPH radical scavenging rate of chalcone derivatives (20 mg/L). Data are expressed as the mean±SD (*n*=3). ^\#^*P\<*0.05 significantly different from control group, ^\*^*P*\<0.05 significantly different from H~2~O~2~ group.Fig. 1

In general, due to the pretreatment with antioxidants for a short time (within 2 h) followed by H~2~O~2~ insult, there is not enough time to induce the expression of cytoprotective protein, and antioxidants may play cytoprotective effect by directly neutralizing ROS[@bib44]. Thus, we chose the screening model of compounds pre-incubation for 1 h to further study the free radical scavenging activity. Notably, all (*E*)-3,4-dihydroxychalcones were capable of relieving the cell injury induced by H~2~O~2~ insult, whereas the (*E*)-3,4-dimethoxychalcones exhibited no cytoprotection ([Fig. 1](#f0005){ref-type="fig"}B).

To further validate their direct free radical scavenging activity, 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was further applied in the test[@bib45]. As shown in [Fig. 1](#f0005){ref-type="fig"}C, as expected, chalcone analogues bearing 3,4-dihydroxyl substituents on ring "A" or "B" all exhibit significant ability to scavenge free radicals directly. In contrast, (*E*)-3,4-dimethoxychalcones were found to be inactive. The result was in line with the damage model with compounds pre-incubation for 1 h, which showed compounds might execute their cytoprotection through scavenging free radicals directly.

More interestingly, compound **21** showed cytoprotection activity only in the model of pre-incubation for 1 h, which suggested that its antioxidant mechanism may *via* directly removing free radicals. Compounds **7**, **13**, **19**, **23**, **25**, **27**, **29**, **31**, **33**, **35**, **39** and **41** were found to have good advantages for cytoprotection at both time points, and thus these compounds may act as both "direct" and "indirect" antioxidants.

2.3. Compound **33** with dual-antioxidant mechanism showed better antioxidant activity than compounds with mono-antioxidant mechanism in vitro {#s0025}
-----------------------------------------------------------------------------------------------------------------------------------------------

So far, compared with antioxidants with mono-antioxidant mechanism, there are no reports about whether those with dual-antioxidant mechanism may have better drug prospects. Based on the promising cytoprotection activity, compound **33** could be considered as a direct and indirect antioxidant. Thus, **33** was selected as the candidate compound with dual-antioxidant mechanism for further investigation. In addition, the molecules that have similar structure to **33** are chosen as control compounds with mono-antioxidant mechanism. Compound **21** mentioned above may be a free radical scavenger. Furthermore, (*E*)-3,4-dimethoxychalcones without phenolic hydroxy showed no effective cytoprotection activity in the study, which suggested that there may be no indirect antioxidants. In our previous study, chalcone derivatives were found to act as antioxidants by activating the antioxidant NRF2 signaling pathway, and compound **1b** without phenolic hydroxy pretreatment for 24 h had an ability to protect against H~2~O~2~-triggered cell apoptosis[@bib43] ([Supporting Information Fig. S1](#s0155){ref-type="sec"}). After pre-incubation with **1b** for 1 h followed by H~2~O~2~ insult, the population of viable cells did not increase ([Supporting Information Fig. S1](#s0155){ref-type="sec"}), which means **1b** may execute the antioxidant activities mainly through activating antioxidant signaling pathway. Immunofluorescence experiments also revealed that NRF2 nuclear translocation was activated by compounds **33** and **1b**, rather than by compound **21** ([Fig. 3](#f0015){ref-type="fig"}A and [Supporting Information Fig. S2](#s0155){ref-type="sec"}). In order to confirm whether compounds **33**, **1b** and **21** could stimulate the related protein coding genes expression in the NRF2-ARE signaling pathway, Western blot experiments were further determined. As showed in [Fig. 2](#f0010){ref-type="fig"}C, compound **21** could not upregulate HO-1 protein expression in PC12 cells, while both compounds **33** and **1b** could elevate HO-1 level. Therefore, according to the above results, compound **33** was proven as a both "direct" and "indirect" antioxidant, while compounds **21** and **1b** were deemed as a free radical scavenger and an activator of cellular antioxidant pathway, respectively, and were used as the control compounds with mono-antioxidant mechanism.Figure 2The cytoprotective effects of **33** on PC12 cells subjected to H~2~O~2~. (A) Cytotoxicity screening of **33** in PC12 cells. The cells were treated with 10 μmol/L of **21**, **33** and **1b** for 24 h, and the cytotoxicity of compounds were determined by the MTT assay. (B) Protection of compound **33** against H~2~O~2~-induced PC12 cell damage. PC12 cells were incubated with 10 μmol/L of **33**, **21**, **1b** for 1, 2, 4, 6, 9,12, 15, 18, 21 and 24 h before exposed to H~2~O~2~ (450 μmol/L) for additional 24 h. Then the cell viability was determined by MTT assay. (C) Elevating the expression level of protein HO-1 by **33**. PC12 cells were incubated with **33** (10 μmol/L), **21**(10 μmol/L), **1b** (10 μmol/L) for 2, 6, 12,18 and 24 h, and the HO-1 was determined by Western blot experiment. (D) **33** protected PC12 cells from H~2~O~2~-induced cell injury. PC12 cells were pretreated with **33** in different doses (2.5, 5 and 10 μmol/L) for 1 or 24 h, then treated with 450 μmol/L H~2~O~2~ for 24 h, and determined by the MTT assay. (E) **33** decreased ROS level in H~2~O~2~-treated PC12 cells. PC12 cells were pre-treated with 10 μmol/L of **33**, ED or TBHQ, then treated with H~2~O~2~ for 4 h, and the ROS level was measured by flow cytometry. (F) Protection of compound **33** by reducing MDA. PC12 cells were pre-incubated with **33** at 2.5, 5 and 10 μmol/L, ED (10 μmol/L) or TBHQ (10 μmol/L) for 1 or 24 h, then treated with 700 μmol/L H~2~O~2~ for 16 h, finally determined by the manufacturer׳s instructions. Data are expressed as the mean±SD (*n*=3). ^\#\#\#^*P\<*0.001, ^\#\#^*P\<*0.01, ^\#^*P\<*0.05 significantly different from control group, ^\*\*\*^*P\<*0.001, ^\*\*^*P\<*0.01, ^\*^*P\<*0.05 significantly different from H~2~O~2~ group.Fig. 2

Generally speaking, ideal antioxidant agents have lower toxicity, so the cytotoxicity of compounds (**1b**, **21** and **33**) toward the PC12 cells were assessed. As shown in [Fig. 2](#f0010){ref-type="fig"}A, there is no apparent cytotoxicity of the tested compounds at 10 μmol/L. To compare the antioxidant activity of these compounds, PC12 cells were pretreated with compounds **1b**, **21** and **33** for 10 time points from 1 to 24 h followed by H~2~O~2~ challenge. The results showed that compound **33** exhibited potent cytoprotection throughout the incubation time, while compounds **21** and **1b** were active only when pretreated for 1--10 h and 9--18 h, respectively, which indicated that compound **33** has better antioxidant activity ([Fig. 2](#f0010){ref-type="fig"}B). To explore the different mechanisms of antioxidant activity among compounds **1b**, **21** and **33**, the expression of HO-1 protein at 0, 2, 6, 12, 18 and 24 h after treatment with compounds in PC12 cells was further determined. As shown in [Fig. 2](#f0010){ref-type="fig"}C, **33** and 1**b** both started to activate the expression of HO-1 at 12 h and could last continuously to 24 and 18 h, respectively, whereas **21** could not induce HO-1 expression. Therefore, these data collectively demonstrated that **21** generally relies on the facile ability of phenols to be oxidized to wield its primary cytoprotection effect, while **1b** was involved in endogenous cellular NRF2 signaling pathway to diminish oxidative damage. Taken together, compared with mono-antioxidant mechanism compound, **33** displayed better protection *in vitro*.

In order to further determine the potential interest of **33** as a cytoprotective agent, PC12 cells were pretreated with **33** for 1 or 24 h, and incubated with H~2~O~2~ for another 24 h. As shown in [Fig. 2](#f0010){ref-type="fig"}D, the population of viable cells increased in a dose-dependent manner. The burst of ROS is unavoidable when cells are stimulated with H~2~O~2~. To confirm the ROS scavenging activity of **33**, we further determined the content of ROS after H~2~O~2~ insult. As shown in [Fig. 2](#f0010){ref-type="fig"}E, pretreatment of the cells with **33** for 1 or 24 h remarkably reduced the ROS accumulation. Malondialdehyde (MDA), a byproduct of polyunsaturated fatty acid peroxidation caused by ROS, is regarded as a significant biomarker of oxidative stress[@bib46]. It is found that addition of **33** for 1 or 24 h significantly reduced the MDA in a dose-dependent manner ([Fig. 2](#f0010){ref-type="fig"}F). Consequently, compound **33** significantly protected PC12 cells from H~2~O~2~-induced cell injury.

2.4. Activation of NRF2-ARE pathway is responsible for the antioxidant activities of compound 33 {#s0030}
------------------------------------------------------------------------------------------------

When NRF2 is activated, it translocates into the nucleus and thus further exerts its transcriptional function. Hence, we examined whether compound **33** can induce the nucleus translocation of NRF2 in PC12 cells by immunofluorescence. ED and TBHQ were used as positive controls. The blue and red staining represent nuclei and NRF2, respectively, and merge represents both. As shown in [Fig. 3](#f0015){ref-type="fig"}A, compared to the blank control group, there was strong fluorescent light in the nucleus, clearly showing that **33** could induce NRF2 translocation and concentration in the nucleus. Authentically, the similar phenomenon occurred when treated with TBHQ and ED. The results supported that **33** was able to promote NRF2 to accumulate in the nuclei.Figure 3Compound **33** activated the antioxidant defense system in PC12 cells. (A) **33** promoted NRF2 translocation into the nucleus. PC12 cells were incubated with **33**, ED and TBHQ at 10 μmol/L for 6 h, and then stained with NRF2 antibody and DAPI. (B) and (C) **33** induced the mRNA expression of *GCLC* and *HO-1*. PC12 cells were incubated with **33** in different doses for 24 h and then evaluated the mRNA level of *GCLC* and *HO*-1 by RT-PCR experiment. (D) **33** induced the protein expression of GCLC and HO-1. PC12 cells were incubated with **33** at 2.5, 5 and 10 μmol/L, TBHQ at 10 μmol/L for 24 h, and the GCLC and HO-1 were determined by Western blot experiment. (E) BSO or ZnPP diminished the protected effect of **33** on H~2~O~2~ induced cell damage. PC12 cells were incubated with GCLC inhibitor BSO or HO-1 inhibitor ZnPP for 1 h, then treated with **33** (10 μmol/L) for 24 h and exposed to H~2~O~2~ (450 μmol/L) for additional 24 h. Finally, MTT assay measured the OD values in 490 nm. Data are expressed as the mean ± SD (*n*=3). ^\#\#\#^*P\<*0.001, ^\#\#^*P\<*0.01, ^\#^*P\<*0.05 significantly different from control group, ^\*\*\*^*P \<* 0.001, ^\*^*P \<* 0.05.Fig. 3

NRF2 can initiate the transcription of phase II genes, the expression of *GCLC* and *HO-1* were further determined. First of all, the *GCLC* and *HO-1* mRNA expression levels induced by **33** were investigated by RT-PCR. As shown in [Fig. 3](#f0015){ref-type="fig"}B--C, **33** clearly increased the *GCLC* and *HO-1* mRNA levels in a dose-dependent manner. The data showed compound **33** treatment could effectively activate the transcription of NRF2-driven antioxidant genes. Furthermore, to elucidate the mechanism of **33**, Western blot assays were used to determine the expression levels of GCLC and HO-1. After PC12 cells were treated with **33** at 2.5, 5 and 10 μmol/L levels for 24 h, the expression of GCLC and HO-1 protein enhanced in a concentration-dependent manner ([Fig. 3](#f0015){ref-type="fig"}D). Especially, **33** at 5 μmol/L exhibited much stronger promoting effects than TBHQ at 10 μmol/L.

To make sure if the expression of GCLC and HO-1 caused by the **33** is responsible for the cytoprotective effects against H~2~O~2~-derived oxidative cell death, BSO and ZnPP, which are specific inhibitors of GCLC and HO-1 respectively, were utilized in this study[@bib43], [@bib44], [@bib47]. As shown in [Fig. 3](#f0015){ref-type="fig"}E, after PC12 cells were pre-treated with ZnPP (15 μmol/L) or BSO (10 μmol/L) for 1 h, there is no obvious adverse effects on the viability of PC12 cells. Applying **33** alone raised the cell viability, while BSO or ZnPP all can cause a dramatic decrease in cell viability induced by **33**. These results suggested that promotion NRF2 translocation into the nucleus and further induction of GCLC and HO-1 expression had a significant function in hindering oxidative stress, and at least partly, explaining the antioxidant activity of **33**. In all, according to the results *in vitro*, it seems that compound **33** is an ROS scavenger and an activator of cellular intrinsic KEAP1*/*NRF2*/*ARE antioxidant pathway at the same time.

2.5. Protective effect of compound **33** was more pronounced than that of mono-antioxidant mechanism compound on cerebral ischemia-reperfusion injury {#s0035}
------------------------------------------------------------------------------------------------------------------------------------------------------

Inspired by the results above, **33** showed significantly higher protection of PC12 cells against oxidative insults through dual antioxidant mechanisms *in vitro.* However, it is still not clear that whether **33** has a better protection than the mono-antioxidant mechanism compound for inhibiting cerebral ischemia-reperfusion injury. Hence, the neuroprotective activity of **33** *in vivo* was further investigated in a rat model of transient focal cerebral ischemia by intraluminal occlusion of the middle cerebral artery (MCAO), which was considered to be the most common reason for inducing I/R-related brain injury in the clinic[@bib48]. Considering that administration of various drugs by intraperitoneal or intravenous injection exists different absorption, distribution, metabolism and excretion (ADME), which could disturb their efficacy, the anti-ischemic stroke effects of **33**, **21** and **1b** were evaluated by pre-injection into lateral ventricles in order to exclude the effect of peripheral pharmacokinetics of drugs. The infarct size of individual rat was evaluated by the 2,3,5-triphenyltetrazolium chloride (TTC) staining[@bib49]. As illustrated in [Fig. 4](#f0020){ref-type="fig"}A--B, as expected, there were no obvious neuronal abnormality in the sham group, whereas the infarct area in the model group and vehicle group of rats significantly increased, as shown in the white region of rat brain sections. But, intracerebroventricular administration of **33** markedly reduced the infarct sizes of I/R rats. Additionally, treatment with **33** improved the neurologic scoring in the brains from ischemic rats. The addition of **21** and **1b** were found to show weak protective effects on infarction damage, respectively ([Fig. 4](#f0020){ref-type="fig"}C). Therefore, the effect of **33** was more pronounced than that of **21** and **1b**, which was in accordance with the cell-based results. It suggested that the compound with dual antioxidant mechanism may have more potential for the treatment of ischemic brain damage compared with the compound with mono-antioxidant mechanism.Figure 4Protective effect of compounds **33**, **21** and **1b** on brain infarct after 72 h reperfusion. (A) TTC staining analysis of the infarcted brain regions. (B) Quantitative analysis of the infracted brain regions. The ratios of infarct area to whole brain areas in individual rats were calculated. (C) Quantitative analysis of neurological score. Cerebral infarction in Sham-operated (Sham) or MACO-reperfusion rats from a representative animal that received normal saline (NS), Veh (polymer:DMSO:distilled water at 50 mg:1 mL:3 mL), or **33**-nanoparticles (0.2 mg/kg), **21**-nanoparticle (0.2 mg/kg), and **1b**-nanoparticles (0.2 mg/kg) intracerebroventricularly 2 h before MCAO. Data are expressed as the mean±SD (*n*=3). ^*\#\#\#*^*P \<* 0.001 significantly different from Sham group, ^\*\*\*^*P* *\<* 0.001, ^\*^*P \<* 0.05 significantly different from control group.Fig. 4

2.6. Therapeutic effects of compound **33** on cerebral ischemia-reperfusion injury {#s0040}
-----------------------------------------------------------------------------------

To date, in addition to preventative therapies for stroke, there has been a more important need to develop effective therapeutic therapies in clinic. Within 3---6 h after stroke onset has been considered as prime time against brain ischemia[@bib50], [@bib51]. Therefore, we next evaluated the therapeutic characteristics of **33** in exerting its effectiveness 3 and 6 h following ischemia-reperfusion injury. To demonstrate the cerebral therapeutic effects of compound **33**, MCAO rat model was also used in this study. Edaravone as a direct antioxidant has been demonstrated to show therapeutic effects on ischemic stroke in the clinic and was used as positive control. Similarly, from the results of TCC staining and neurological scoring, **33** showed more significant therapeutic effect than edaravone when administration conducted 3 or even 6 h after I/R induction ([Fig. 5](#f0025){ref-type="fig"}A--C).Figure 5Therapeutic effect of compound **33** on cerebral ischemia-reperfusion injury. (A) TTC staining analysis of the infarcted brain regions. Quantitative analysis of the infracted brain regions (B) and neurological score (C). (D) and (E) The locomotion trace of the mice in the chamber for a period of 5 min. All animals were divided into seven groups: sham-operated group, NS group, Veh (Cremophor:PBS at 3:97) group. **33** (15 mg/kg, 3 h) + MCAO group, **33** (15 mg/kg, 6 h) + MCAO group, ED (15 mg/kg, 3 h) + MCAO group and ED (15 mg/kg, 6 h) + MCAO group. All rats received drug intraperitoneally 3 or 6 h after MCAO. Data are expressed as the mean±SD (*n*=3). ^*\#\#\#*^*P\<*0.001, ^*\#\#*^*P\<*0.01 significantly different from Sham group, ^\*\*\*^*P \<* 0.001, ^\*\*^*P\<*0.01, ^\*^*P* *\<* 0.05 significantly different from control group.Fig. 5

Cerebral ischemia is known to produce severe behavioral deficits, and bilateral cerebral artery occlusion (BCAO), as another model, was applied for evaluating its protection activity by open field test to estimate locomotor activity of the tested mice. Their total distance of the in-between 5 min traveled during the observation period was collected and analyzed. As shown in [Fig. 5](#f0025){ref-type="fig"}D--E, no obvious ischemia-induced barriers to behavior were observed in sham-operated group. However, the I/R model and vehicle-treated group of mice showed prominent behavioral deficits and the locomotor activity decreased markedly compared with the sham-operated group. In contrast, the neurobehavioral function of compound **33** or edaravone treated mice had obviously improved at 3 h after cerebral ischemia-reperfusion injury. Especially, when intraperitoneal injection of **33** even 6 h after I/R onset, it still had dramatic improvement in exercise behavior, which had even much stronger protective effect than edaravone. In all, these data showed that compound **33** could emerge as a promising anti-ischemic stroke drug candidate.

3. Discussion {#s0045}
=============

Excessive production of ROS is known to lead to acute ischemic injury in various organs, and numerous studies have demonstrated antioxidant therapy is considered as an effective strategy in ischemic disorders[@bib52], [@bib53], [@bib54], [@bib55], [@bib56]. For the current status of antioxidants, this research not only offers novel dual-antioxidant mechanism strategies and concepts on oxidative stress-related diseases treatment, but also provides promising candidate antioxidant drugs with dual-antioxidant mechanism.

Attenuation acute ischemic injury can be mediated by direct and indirect antioxidants. Among them, *N*-acetylcysteine (NAc) has been extensively used as a powerful ROS scavenger and potent neuroprotective actions for the treatment of acute ischemic stroke and rhabdomyolysis-induced acute kidney injury in animal models, respectively[@bib57], [@bib58]. As for indirect antioxidants, such as tert-butylhydroquinone, which has been shown to enhance NRF2 signaling activity and protect against ROS in various brain cells *in vitro*[@bib59], [@bib60], [@bib61]. Comparing the direct and indirect antioxidants, the study of Jokod showed that indirect antioxidants were more beneficial for cytoprotection than direct antioxidants *in vitro*[@bib62]. Moreover, some antioxidants, including melatonin and resveratrol, appear to play a dual-antioxidant protective role as direct and indirect antioxidants[@bib63], [@bib64], [@bib65].

Up till now, there was no study about whether the compounds with dual-antioxidant mechanism may have a better prospect than the ones with single-antioxidant mechanism in acute ischemic stroke. In the present study, compound **33** not only scavenged ROS directly, but also activated NRF2 pathway, and thus it could be considered a both direct and indirect antioxidant. Notably, when PC12 cells were pretreated with **33** for 10 time points from 1 to 24 h followed by H~2~O~2~ insult, **33** exhibited excellent cytoprotection at all the incubation time. For mono-antioxidant compounds, when pretreated with compound **21** as direct antioxidant, the cytoprotection against H~2~O~2~ lasted 1--10 h, and when pretreatment with compound **1b** as indirect antioxidant showed cytoprotection only for 9--18 h. Furthermore, interestingly, compound **33** showed a preferable role for neuroprotecting against cerebral ischemia-reperfusion injury in animal models compared with compounds **21** and **1b**. Taken together, all results suggested that drugs with dual-antioxidant mechanism might be more pronounced than that with single-antioxidant mechanism, which could provide novel and promising strategies and concepts for drug research on antioxidant and stroke treatment.

Natural or synthetic bioactive chalcones have attracted enormous attention in drug exploration due to their low toxicity and various biological activities, especially since they were found to prevent oxidative stress-induced neurodegenerative disorders. For instance, xanthohumol showed protection against oxidative damage in PC12 cells *via* activating NRF2 enzymes[@bib38]. The study of Jeon also demonstrated chalcone derivatives displayed neuroprotective effects against oxidative stress-induced apoptosis in SH-SY5Y cells[@bib66]. In our present study, after treatment with chalcone analogue **33** in both BCAO and MCAO models, all exhibited significant protective effects. Divertingly, compound **33** exerted higher central protection than edaravone at the same dose when administration conducted 3 or even 6 h after I/R induction. Therefore, **33** could serve as a potent candidate antioxidant drug for anti-ischemic stroke drug research and other ischemic disorders treatment.

Phenolic compounds possess high antioxidant activity and are potent regulators of cellular redox status, which have been frequently considered as potent antioxidants. Natural chalcones bearing 3,4-dihydroxyl groups, such as butein, sappanchalcone and okanin, are particularly effective antioxidants[@bib67], [@bib68], [@bib69]. Chiruta et al.[@bib70] reported chalcone derivatives containing catechol group contributed to neuroprotective activity and maintenance of GSH. In addition, Dziedzic et al.[@bib71] revealed that molecules bearing ortho-dihydroxyl possess significantly higher antioxidant activity than those bearing no such functionalities, which may be due to the abstraction of the two hydrogen atoms of the ortho-position hydroxyls respectively, to form a quinone structure. Benayahoum et al.[@bib72] reported the great reactivity of the ortho-dihydroxyl system is possibly due to the smaller dissociation energy of the O-H bond. Moreover, compounds including 3,4-dihydroxyl groups on benzene ring were found to be more potent antioxidant than resveratrol[@bib73]. Hence, chalcone derivatives bearing 3,4-dihydroxyl are favorable for the development of effective antioxidants.

In our study, chalcone analogues bearing 3,4-dihydroxyl groups on ring "A" or ring "B" were designed and synthesized. After PC12 cells were pretreated with (*E*)-3,4-dihydroxychalcones for a short time (1 h) followed by H~2~O~2~ challenge, all compound markedly promoted cell viability, while chalcone derivatives bearing a hydroxyl group or no hydroxyl group remained inactive. Additionally, the results of DPPH assay confirmed the above results, which suggested the (*E*)-3,4-dihydroxychalcones could scavenge ROS directly. When pretreated for 24 h, there are many 3,4-dihydroxychalcone derivatives showing advantageous cytoprotection. Interestingly, compared with 3,4-dihydroxyl groups on ring "B", chalcone analogues with 3,4-dihydroxyl groups on ring "A" all showed significant cytoprotection and had a great improvement on antioxidant capacity, which suggested that the presence of 3,4-dihydroxyl groups on ring "A" may be good for antioxidant activity. Given that the number of (*E*)-3,4-dihydroxychalcones is limited, further research is needed to establish a clearer quantitative structure---activity relationship between structure and cytoprotection with more compounds. Furthermore, compound **33** containing 3,4-dihydroxyl groups on ring "A" with the best antioxidant activity was screened out, and further study showed that **33** could activate NRF2 pathway. So hypothetically, stimulating NRF2 pathway may also occurred in other cytoprotective chalcone analogues containing 3,4-dihydroxy groups on "A" ring. Taken together, chalcone analogues with 3,4-dihydroxyl groups on ring "A" presented important neuroprotective activity *via* directly scavenging ROS and indirectly through NRF2 pathway activation. Therefore, (*E*)-3,4-dihydroxychalcone may be considered as a promising structural element for designing antioxidant compounds with dual-antioxidant mechanism.

4. Conclusions {#s0050}
==============

In the research of antioxidant field, there are no researches on the antioxidant agents with novel dual-antioxidant mechanism of directly scavenging ROS and indirectly through activation of antioxidant pathway. It is also unclear whether antioxidants with dual antioxidant mechanisms have broader application prospects. Our recent research had led to the design and development of a series of antioxidants and found a number of excellent antioxidants with scavenging ROS directly and indirectly. The most potent compound **33** not only showed protection of H~2~O~2~-induced oxidative damage in PC12 cells through scavenging free radicals directly and activating NRF2 pathway at the same time, but also played protective and therapeutic roles against ischemia/reperfusion-related brain injury in animals. More importantly, compound **33** were superior to compounds (only free radical scavengers or NRF2 pathway stimulators) both *in vitro* and *in vivo*. Thus, our present study found a new candidate drug for cerebral ischemia-reperfusion injury treatment, clarified that the dual antioxidant mechanisms have a better prospect for drug development, and provided new ideas and tactics for drug research on stroke and other oxidative stress-induced diseases treatment.

5. Experimental {#s0055}
===============

5.1. Chemistry {#s0060}
--------------

All chemical reagents were obtained commercially from Sigma---Aldrich (St Louis, MO, USA), Aladdin (Shanghai, China) and used without further purification unless otherwise noted. Reactions were monitored by thin-layer chromatography TLC using silica gel GF254, and the chromatograms were conducted on silica gel (200--300 mesh) and observed under UV light at 254 and 365 nm. Melting points (m.p.) are uncorrected and were measured in open capillary tubes on a Fisher---Johns melting apparatus. Mass spectra (MS) were recorded on an Agilent 1100 LC---MS (Agilent, Palo Alto, CA, USA). ^1^H NMR and ^13^C NMR spectra were obtained from 600 MHz spectrometer (Bruker Corporation, Switzerland). Chemical shifts are reported in *δ* units (ppm) relative to TMS as internal standard. Coupling constants (*J*) are expressed in Hz, and splitting patterns are described as follows: s=singlet; d=doublet; t=triplet; q=quartet; m=multiplet; dd=doublet of doublets; dt=doublet of triplets.

### 5.1.1. General procedure for the synthesis of chalcones {#s0065}

A mixture of the corresponding acetophenone (1 eq.) and the corresponding aldehyde (1 eq.) in anhydrous EtOH was stirred at room temperature for 5 min. Then NaOH or HCl (gas) was added into the solution to catalyze the reaction. The reaction mixture was stirred at room temperature until aldehyde was consumed (usually 12--24 h). Completion of the reaction was monitored by thin layer chromatography using ethyl acetate/hexanes as the solvent system. The reaction was quenched by pouring into 50 mL of stirring ice water. If the product precipitated out after quenching with cold water, it was filtered off and crystallized with hot ethanol. In other cases, the products were purified by using silica gel chromatography. Compounds **1**--**7**, **9**--**10**, **13**, **14**, **16**, **19**--**20**, **22**, **24**, **26**, **28, 32, 36**, **38** and **40** were published previously in the literature[@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], and their spectral data are in the [Supporting Information](#s0155){ref-type="sec"}. The spectral data of novel or unreported compounds are listed as follows.

***(E)-3-(3,4-Dimethoxyphenyl)-1-(4-ethoxyphenyl)prop-2-en-1-one (8)***: Yellow power, 67.6% yield, m.p. 88.9--93.4 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 8.165 (d, *J=*9.0 Hz, 2 H, H-2′, H-6′), 7.839 (d, *J=*15.5 Hz, 1 H, H-*β*), 7.683 (d, *J=*15.5 Hz, 1 H, H-*α*), 7.544 (s, 1 H, H-2), 7.379 (d, *J=*8.5 Hz, 1 H, H-5), 7.069 (d, *J=*9.0 Hz, 2 H, H-3′, H-5′), 7.022 (d, *J=*8.5 Hz, 1 H, H-6), 4.145 (q, *J=*7.0 Hz, 2 H, OCH~2~-4′), 3.877 (s, 3 H, OCH~3~-3), 3.824 (s, 3 H, OCH~3~-4), 1.369 (t, *J=*6.5 Hz, 3 H, CH~3~); ^13^C NMR (DMSO*-d*~6~) *δ* 187.25, 162.35, 151.13, 149.53, 143.53, 130.76 (2), 130.56, 127.67, 123.64, 119.62, 114.27 (2), 111.60, 110.82, 63.52, 55.74, 55.58, 14.45. HR-MS *m/z* 313.1436 \[M + H\]^+^, Calcd. for C~19~H~20~O~4~: 312.1362.

***(E)-3-(3,4-Dihydroxyphenyl)-1-(2-fluorophenyl)prop-2-en-1-one (11)***: Yellow green powder, 72.6% yield, m.p. 174.7--175.8 °C. ^1^H NMR (Acetone-*d*~6~) *δ* 8.581 (s, 1 H, OH-3), 8.255 (s, 1 H, OH-4), 7.760 (dd, *J=*1.8 Hz, *J=*7.2 Hz, 1 H, H-6′), 7.633--7.645 (m, 1 H, H-4′), 7.572 (dd, *J=*1.2 Hz, *J=*15.6 Hz, 1 H, H-*β*), 7.331--7.357 (m, 1 H, H-5′), 7.281--7.299 (m, 1 H, H-3′), 7.266 (d, *J=*1.8 Hz, 1 H, H-2), 7.213 (dd, *J=*2.4 Hz, *J=*15.6 Hz, 1 H, H-*α*), 7.142 (dd, *J=*2.4 Hz, *J=*8.4 Hz, 1 H, H-6), 6.904 (d, *J=*7.8 Hz, 1 H, H-5); ^13^C NMR (DMSO*-d*~6~) *δ* 188.55, 161.02, 159.02, 149.13, 145.70, 133.73, 130.30, 127.32, 125.71, 124.75, 122.54, 122.09, 116.58, 115.87, 114.97. HR-MS *m/z* 281.0593 \[M + Na\]^+^, Calcd. for C~15~H~11~FO~3~: 258.0692.

***(E)-1-(3,4-Dimethoxyphenyl)-3-(2-fluorophenyl)prop-2-en-1-one (12)***: Yellow powder, 67.4% yield, m.p. 90.5--92.4 °C. ^1^H NMR (CDCl~3~) *δ* 7.591 (d, *J=*7.8 Hz, 1 H, H-4′), 7.564--7.536 (m, 2 H, H-6′, H-5′), 7.489 (d, *J=*14.4 Hz, 1 H, H-*β*), 7.403 (d, *J=*1.8 Hz, 1 H, H-6), 7.310--7.288 (m, 2 H, H-3′, H-2), 7.188 (d, *J=*16.2 Hz, 1 H, H-*α*), 7.002 (d, *J=*8.4 Hz, 1 H, H-5), 3.809 (s, 6 H, OCH~3~-3, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.93, 151.45, 149.04, 145.01, 137.81, 136.51, 130.29 (2), 128.77 (2), 127.40, 124.07, 119.28, 111.58, 110.93, 55.75, 55.59. HR-MS *m/z* 287.1071 \[M + H\]^+^, Calcd. for C~17~H~15~FO~3~: 286.1005.

***(E)-3-(3,4-Dihydroxyphenyl)-1-(4-fluorophenyl)prop-2-en-1-one (15)***: Yellow power, 78.8% yield, m.p. 224.4--226.0 °C. ^1^H NMR (Acetone-*d*~6~) *δ* 8.594 (s, 1 H, OH-3), 8.212 (t, *J=*1.8 Hz, 2 H, H-3′, H-5′), 8.151 (s, 1 H, OH-4), 7.687 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.624 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.336 (d, *J=*1.8 Hz, 1 H, H-2), 7.298 (t, *J=*8.7 Hz, 2 H, H-2′, H-6′), 7.210 (t, *J=*8.4 Hz, 1 H, H-6), 6.905 (d, *J=*8.4 Hz, 1 H, H-5); ^13^C NMR (DMSO-*d*~6~) *δ* 191.01, 152.10, 148.76, 145.85, 145.58, 145.11, 131.24, 131.16, 128.86, 126.21, 124.40, 122.23, 118.19, 115.50, 114.40. HR-MS *m/z* 281.0593 \[M + Na\]^+^, Calcd. for C~15~H~11~FO~3~: 258.0692.

***(E)-1-(3,4-Difluorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one (17)***: Yellow power, 77.9% yield, m.p. 234.9--236.4 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 9.803 (s, 1 H, OH-3), 9.123 (s, 1 H, OH-4), 8.178--8.214 (m, 1 H, H-2′), 8.019--8.037 (m, 1 H, H-6′), 7.600--7.667 (m, 1 H, H-5′), 7.654 (d, *J=*16.2 Hz, 1 H, H-*β*), 7.628 (d, *J=*16.2 Hz, 1 H, H-*α*), 7.302 (d, *J=*2.4 Hz, 1 H, H-2), 7.218 (dd, *J=*2.4 Hz, *J=*8.4 Hz, 1 H, H-6), 6.819 (d, *J=*8.4 Hz, 1 H, H-5); ^13^C NMR (DMSO-*d*~6~) *δ* 186.38, 149.00, 145.80, 145.60, 126.16, 125.99, 125.93, 122.49, 117.92, 117.78, 117.74, 117.67, 117.53, 115.82, 115.70. HR-MS *m/z* 277.0682 \[M + H\]^+^, Calcd. for C~15~H~10~F~2~O~3~: 276.0598.

***(E)-1-(3,4-Difluorophenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (18)***: Yellow power, 75.0% yield, m.p. 118.6--120.4 °C. ^1^H NMR (CDCl~3~) *δ* 7.846--7.880 (m, 1 H, H-6′), 7.801--7.809 (m, 1 H, H-2′), 7.788 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.309 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.262--7.311 (m, 1 H, H-5′), 7.248 (dd, *J=*1.8 Hz, *J=*8.4 Hz, 1 H, H-6), 7.156 (d, *J=*1.8 Hz, 1 H, H-2), 6.913 (d, *J=*7.8 Hz, 1 H, H-5), 3.976 (s, 3 H, OCH~3~-3), 3.945 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 182.45, 146.59, 144.15, 140.69, 122.32, 120.00, 119.94, 118.18, 113.59, 112.58, 112.44, 112.26, 112.12, 106.00, 105.04, 50.78 (2). HR-MS *m/z* 305.0982 \[M + H\]^+^, Calcd. for C~17~H~14~F~2~O~3~: 304.0911.

***(E)-1-(3,5-Difluorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one (21)***: Yellow powder, 46.6% yield, m.p. 180.9--183.2 °C. ^1^H NMR (Acetone-*d*~6~) *δ* 7.729--7.764 (m, 3 H, H-*β*, H-2′, H-6′), 7.672 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.379 (d, *J=*1.8 Hz, 1 H, H-2), 7.305 (dd, *J=*2.4 Hz, *J=*8.4 Hz, 1 H, H-4′), 7.251 (dd, *J=*1.8 Hz, *J=*7.8 Hz, 1 H, H-6), 6.912 (d, *J=*7.8 Hz, 1 H, H-5); ^13^C NMR (DMSO-*d*~6~) *δ* 191.00, 152.10, 149.17, 146.44, 145.86, 145.60, 128.86, 126.12, 124.39, 122.71, 117.68, 115.95, 115.70, 115.50, 114.40. HR-MS *m/z* 277.0682 \[M + H\]^+^, Calcd. for C~15~H~8~F~2~O~3~: 276.0598.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (23)***: Yellow crystal, 81.6% yield, m.p. 129.3--132.3 °C. ^1^H NMR (CDCl~3~) *δ* 7.800 (d, *J=*9.0 Hz, 2 H, H-2, H-6), 7.698 (d, *J=*15.0 Hz, 1 H, H-*β*), 7.614 (d, *J=*15.0 Hz, 1 H, H-*α*), 7.607 (dd, *J=*2.4 Hz, *J=*8.4 Hz, 1 H, H-6′), 7.499 (d, *J*=2.4 Hz, 1 H, H-2′), 7.002 (d, *J=*9.0 Hz, 2 H, H-3, H-5), 6.850 (d, *J=*8.4 Hz, 1 H, H-5′), 3.814 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.14, 161.04, 150.66, 145.41, 142.32, 130.46×2, 129.84, 127.54, 121.87, 119.74, 115.40, 115.17, 114.36 (2), 55.32. HR-MS *m/z* 271.0995 \[M + H\]^+^, Calcd. for C~16~H~14~O~4~: 270.0892.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-1-one (25)***: Yellow powder, 43.5% yield, m.p. 153.8--156.6 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 7.601 (d, *J=*3.6 Hz, 1 H, H-*β*), 7.583 (t, *J=*5.4 Hz, 1 H, H-6′), 7.530 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.491 (d, *J=*2.4 Hz, 1 H, H-2′), 7.273 (d, *J=*1.8 Hz, 1 H, H-2), 7.247 (dd, *J=*2.4 Hz, *J=*2.4 Hz, 1 H, H-6), 6.987 (d, *J=*6.4 Hz, 1 H, H-5′), 6.855 (d, *J=*7.8 Hz, 1 H, H-5), 3.835 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.12, 150.70, 149.97, 146.65, 145.40, 142.82, 129.86, 127.85, 121.79, 121.56, 119.55, 115.31, 115.08, 114.62, 111.98, 55.66. HR-MS *m/z* 287.0914 \[M + H\]^+^, Calcd. for C~16~H~14~O~5~: 286.0841.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one (27)***: Yellow powder, 43.9% yield, m.p. 191.3--192.9 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 7.928 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.819 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.626 (dd, *J=*3.0 Hz, *J=*2.4 Hz, 1 H, H-6), 7.505 (d, *J=*1.8 Hz, 1 H, H-6′), 7.494 (d, *J=*2.4 Hz, 1 H, H-2′), 7.044--6.997 (m, 2 H, H-5, H-5′), 6.859 (d, *J=*20.4 Hz, 1 H, H-3), 3.835 (s, 3 H, OCH~3~-2), 3.790 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.31, 162.70, 159.73, 150.50, 145.36, 137.27, 130.01, 129.95, 121.62, 119.35, 116.19, 115.30, 115.07, 106.23, 98.35, 55.78, 55.48. HR-MS *m/z* 301.1068 \[M + H\]^+^, Calcd. for C~17~H~16~O~5~: 300.0998.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (29)***: Red-brown power, 50.8% yield, m.p. 143.2--147.9 °C. ^1^H NMR (CDCl~3~) *δ* 8.107 (d, *J=*16.2 Hz, 1 H, H-*β*), 7.635 (d, *J=*16.2 Hz, 1 H, H-*α*), 7.773 (s, 1 H, H-2′), 7.591--7.635 (m, 2 H, H-5′, H-6′), 7.381 (t, *J=*7.8 Hz, 1 H, H-4), 6.937--7.008 (m, 3 H, H-3, H-5, H-6′), 3.924 (s, 3 H, OCH~3~-2); ^13^C NMR (DMSO-*d*~6~) *δ* 187.38, 158.10, 150.81, 145.46, 137.06, 131.80, 129.72, 128.40, 123.22, 122.09, 121.91, 120.67, 115.33, 115.12, 111.74, 55.67. HR-MS *m/z* 271.0995 \[M + H\] ^+^, Calcd. for C~16~H~14~O~4~: 270.0892.

***(E)-1-(3,4-Dimethoxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (30)***: Yellow powder, 58.9% yield, m.p. 53.9--55.0 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 8.035 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.989 (dd, *J=*1.8 Hz, *J=*1.8 Hz, 1 H, H-6′), 7.913--7.866 (m, 2 H, H-2′, H-6), 7.599 (d, *J=*2.4 Hz, 1 H, H-3), 7.468-7.440 (m, 1 H, H-4), 7.118 (t, *J=*15.6 Hz, 2 H, H-5, H-5′), 7.044 (t, *J=*15.0 Hz, 1 H, H-*α*), 3.907 (s, 3 H, OCH~3~-3′), 3.879 (s, 3 H, OCH~3~-4′), 3.866 (s, 3 H, OCH~3~-2); ^13^C NMR (DMSO-*d*~6~) *δ* 187.52, 158.16, 153.14, 148.85, 137.63, 131.84, 130.74, 128.32, 123.24, 123.08, 121.75, 120.56, 111.55, 110.75, 55.48 (3). HR-MS *m/z* 299.1212 \[M + H\]^+^, Calcd. for C~18~H~18~O~4~: 298.1205.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(2,3-dimethoxyphenyl)prop-2-en-1-one (31)***: Brown yellow powder, 20.0% yield, m.p. 160.2--163.2 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 9.960 (s, 1 H, OH-3′), 9.407 (s, 1 H, OH-4′), 7.905 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.813 (d, *J=*16.0 Hz, 1 H, H-*α*), 7.624 (d, *J=*8.0 Hz, 1 H, H-6′), 7.572 (s, 1 H, H-6), 7.521 (s, 1 H, H-5), 7.139(s, 2 H, H-2′, H-5′), 6.878 (d, *J=*8.0 Hz, 1 H, H-4), 3.845 (s, 3 H, OCH~3~-2), 3.798 (s, 3 H, OCH~3~-3); ^13^C NMR (DMSO-*d*~6~) *δ* 187.30, 152.77, 150.91, 148.10, 145.49, 136.50, 129.52, 128.44, 124.25, 123.10, 122.03, 119.15, 115.36, 115.12, 114.76, 60.86, 55.81. HR-MS *m/z* 301.1068 \[M + H\]^+^, Calcd. for C~17~H~16~O~5~: 300.0998.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(2,5-dimethoxyphenyl)prop-2-en-1-one (33)***: Yellow powder, 56.8% yield, m.p. 95.4--97.9 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 9.869 (s, 1 H, OH-3′), 9.320 (s, 1 H, OH-4′), 7.926 (d, *J=*19.2 Hz, 1 H, H-*β*), 7.803 (d, *J=*19.2 Hz, 1 H, H-*α*), 7.615 (d, *J=*9.6 Hz, 1 H, H-6′), 7.495 (d, *J=*19.2 Hz, 2 H, H-2′, H-5′), 7.029 (d, *J=*8.4 Hz, 2 H, H-3, H-6), 6.872 (d, *J=*9.0 Hz, 1 H, H-4), 3.845 (s, 3 H, OCH~3~-2), 3.799 (s, 3 H, OCH~3~-5); ^13^C NMR (DMSO-*d*~6~) *δ* 187.36, 153.26, 152.56, 150.84, 145.45, 136.79, 129.70, 123.79, 122.28, 122.04, 117.63, 115.38, 115.07, 113.04, 112.62, 56.15, 55.67. HR-MS *m/z* 301.1068 \[M + H\]^+^, Calcd. for C~17~H~16~O~5~: 300.0998.

***(E)-3-(2,5-Dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (34)***: Yellow powder, 74.3% yield, m.p. 72.5--73.4 °C. ^1^H NMR (CDCl~3~) *δ* 8.066 (d, *J=*15.5 Hz, 1 H, H-*β*), 7.680 (d, *J=*8.0 Hz, 1 H, H-6′), 7.607 (d, *J=*18.0 Hz, 2 H, H-2′, H-*α*), 7.178 (s, 1 H, H-6), 6.938 (d, *J=*7.5 Hz, 2 H, H-3, H-4), 6.884 (d, *J=*8.5 Hz, 1 H, H-5′), 3.974 (s, 6 H, OCH~3~-3′, OCH~3~-4′), 3.878 (s, 3 H, OCH~3~-2), 3.826 (s, 3 H, OCH~3~-5); ^13^C NMR (CDCl~3~) *δ* 189.25, 153.59, 153.30, 153.14, 149.22, 139.33, 131.61, 124.86, 123.00 (2), 116.86, 113.97, 112.53, 111.03, 110.06, 56.16, 56.07, 56.05, 55.87. HR-MS *m/z* 329.1389 \[M + H\]^+^, Calcd. for C~19~H~20~O~5~: 328.1311.

***(E)-3-(4-Chlorophenyl)-1-(3,4-dihydroxyphenyl)prop-2-en-1-one (35)***: Light powder, 34.8% yield, m.p. 216.4--217.8 °C. ^1^H NMR (DMSO-*d*~6~) *δ* 9.980 (s, 1 H, OH-3′), 9.386 (s, 1 H, OH-4′), 7.906 (s, 1 H, H-*β*), 7.886 (t, *J=*15.0 Hz, 2 H, H-6, H-2), 7.666-7.623 (m, 2 H, H-2′, H-6′), 7.523 (d, *J=*2.4 Hz, 2 H, H-3, H-5), 7.507 (s, 1 H, H-*α*), 6.869 (d, *J=*8.4 Hz, 1 H, H-5′); ^13^C NMR (DMSO-*d*~6~) *δ* 188.55, 161.02, 159.02, 149.13, 145.70, 133.73, 130.30, 127.32, 125.71, 124.75, 122.54, 122.09, 116.58, 115.87, 114.97. HR-MS *m/z* 275.0502 \[M + H\]^+^, Calcd. for C~15~H~11~ClO~3~: 274.0397.

***(E)-3-(3,4-Dichlorophenyl)-1-(3,4-dihydroxyphenyl)prop-2-en-1-one (37)***: Dark purple syrupy, 49.2% yield. ^1^H-NMR (DMSO-*d*~6~) *δ* 9.808 (s, 1 H, OH-3′), 9.122 (s, 1 H, OH-4′), 8.196 (t, *J=*9.0 Hz, 1 H, H-*β*), 8.025 (s, 1 H, H-2′), 7.643-7.591 (m, 3 H, H-*α*, H-6′, H-6), 7.305 (s, 1 H, H-2), 7.218 (d, *J=*9.5 Hz, 1 H, H-5′), 6.956 (d, *J=*8.0 Hz, 1 H, H-5). ^13^C NMR (DMSO-*d*~6~) *δ* 186.94, 151.16, 145.53, 139.55, 135.85, 132.29, 131.76, 130.88, 129.91, 129.39, 128.82, 124.36, 122.43, 115.46, 115.04. HR-MS *m/z* 308.9991 \[M + H\]^+^, Calcd. for C~15~H~10~Cl~2~O~3~: 308.0007.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (39)***: Yellow powder, 56.4% yield, m.p. 118.9--121.0 °C. ^1^H NMR (CDCl~3~) *δ* 9.944 (s, 1 H, OH-3′), 9.370 (s, 1 H, OH-4′), 7.814 (d, *J=*12.0 Hz, 1 H, H-*β*), 7.671 (dd, *J=*2.4 Hz, *J=*2.4 Hz, 1 H, H-6′), 7.609 (d, *J=*15.0 Hz, 1 H, H-*α*), 7.533 (d, *J=*2.4 Hz, 1 H, H-2′), 7.195 (s, 2 H, H-2, H-6), 6.882 (d, *J=*7.8 Hz, 1 H, H-5′), 3.865 (s, 6 H, OCH~3~-3, OCH~3~-5), 3.712 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.21, 153.09 (2), 150.82, 145.45, 142.85, 139.51, 130.48, 129.72, 122.13, 121.43, 115.43, 115.00, 106.30 (2), 60.10, 56.11 (2). HR-MS *m/z* 353.0999 \[M + Na\]^+^, Calcd. for C~18~H~18~O~6~: 330.1103.

***(E)-1-(3,4-Dihydroxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (41)***: Yellow power, 64.3% yield, m.p. 109.5--111.0 °C. ^1^H NMR (CDCl~3~) *δ* 7.737 (d, *J=*15.6 Hz, 1 H, H-*β*), 7.648 (dd, *J=*1.8 Hz, *J=*1.8 Hz, 1 H, H-6′), 7.608 (d, *J=*15.6 Hz, 1 H, H-*α*), 7.519 (d, *J=*1.8 Hz, 1 H, H-2′), 7.508 (d, *J=*1.8 Hz, 1 H, H-2), 7.337 (dd, *J=*1.8 Hz, *J=*1.8 Hz, 1 H, H-6), 7.015 (d, *J=*8.4 Hz, 1 H, H-5′), 6.867 (d, *J=*8.4 Hz, 1 H, H-5), 3.863 (s, 3 H, OCH~3~-3), 3.817 (s, 3 H, OCH~3~-4); ^13^C NMR (DMSO-*d*~6~) *δ* 187.36, 153.26, 152.56, 150.84, 145.45, 136.79, 129.70, 123.79, 122.28, 122.04, 117.63, 115.38, 115.07, 113.04, 112.62, 56.15, 55.67. HR-MS *m/z* 301.1068 \[M + H\]^+^, Calcd. for C~17~H~16~O~5~: 300.0998.

5.2. Pharmacology {#s0070}
-----------------

### 5.2.1. DPPH assay {#s0075}

The DPPH assay measured hydrogen atom (or one electron) donating activity and hence provided an evaluation of antioxidant activity due to free radical scavenging[@bib90]. The test was prepared as described previously[@bib44], [@bib91].

### 5.2.2. Cell culture {#s0080}

PC12 cells, rat pheochromocytoma cell lines, were obtained from the Cell Storage Center of Wuhan University (Wuhan, China). Cells were grown in 1× DMEM supplemented with 10% fetal bovine serum (FBS), containing 100 U/mL penicillin and 100 U/mL streptomycin, and incubated at 37 °C with 5% CO~2~.

### 5.2.3. MTT assay {#s0085}

3-\[4,5-Dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide, thiazolyl blue (MTT) assay was used to measure cell viability. Briefly, cells were seeded in 96-well plates and cultured for 24 h. After appropriate treatments, the cells were incubated with 20 μL MTT (0.5 mg/mL). Following incubation at 37 °C for 4 h, media were aspirated from each well and DMSO (120 μL) was added. The absorbance was measured at *λ*=490 nm using a Microplate Reader (Bio-Rad, USA). Assays were repeated at least three times.

### 5.2.4. Lipid peroxidation assay {#s0090}

Levels of Malondialdehyde (MDA) were determined using the assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer׳s instruction. At the end of the drug treatment, supernatants in the cells were collected through centrifugation. Supernatants were mixed with TBA (0.37%) solution and then boiled for 15 min at 100 °C. The samples were rapidly cooled to room temperature, and were determined with a microplate reader at a wavelength of 532 nm.

### 5.2.5. Detection of reactive oxygen species {#s0095}

Intracellular ROS generation was assessed with dichlorodihydrofluorescein diacetate (DCFH-DA, Beyotime Biotechnology, Shanghai, China). Cells were stained with 1 μL DCFH-DA (10 μmol/L) for 30 min at 37 °C in the dark. Cells were trypsinized, harvested, washed three times with PBS, resuspended in PBS and then analyzed by flow cytometry (Becton Dickinson, USA).

### 5.2.6. Immunofluorescence {#s0100}

PC12 cells were fixed with 4% paraformaldehyde for 20 min at room temperature and washed three times with PBS. The cells were permeabilized in 0.1% TritonX-100 (Sigma---Aldrich St. Louis, MO, USA) for 15 min and blocked in 1% BSA for 1 h at room temperature. After being washed, the cells were incubated with a 1:200 dilution of primary NRF2 antibody (sc-13032, Santa Cruz Biotechnology, USA, 1:200) at 4 °C overnight and incubated with appropriate secondary antibody (sc-13032, goat anti-rabbit IgG-PE, Santa Cruz Biotechnology, USA, 1:300) for 1 h at room temperature. Cell nuclei were stained with DAPI. The images were acquired with the fluorescence microscope (Nikon, Japan).

### 5.2.7. Real-time PCR analyses {#s0105}

After various treatments, the cells were collected and total RNA was extracted. Then, reverse transcription (RT) was performed with M-MLV Reverse Transcriptase (Thermo Fisher Scientific, MA, USA) as following: 65 °C for 5 min for the reverse transcription. And the real-time PCR assay was performed at 37 °C for 50 min and 70 °C for 15 min for the PCR reaction, with 40 cycles. Relative levels of mRNA were analysed by the following primers.

For m*HO-1*: 5′-GCCTGCTAGCCTGGTTCAAG-3′; 5′-AGCGGTGTCTGGGATGA ACTA-3′.

For m*GCLC*: 5′-GTCCTCAGGTGA CATTCCAAGC-3′; 5′-TGTTCTTCAGG GGCTCCAGTC-3′.

For m*GAPDH*: 5′-AAGCTGGTCATCA ACGGGAAAC-3′; 5′-GAAGACGCCAG TAGACTCCACG-3′.

Relative mRNA expression values were calculated by the^---ΔΔCt^ method[@bib92].

### 5.2.8. Western blot analysis {#s0110}

PC12 cells were incubated in 6-well plates at a density of 3×10^5^ and incubated for 24--48 h at 37 °C. After suitable treatments, the cells were collected and lysed with ice-cold RIPA lysis buffer. Equal amounts of protein samples (80 μg) were separated on a 10% SDS-PAGE gel and transferred electrophoretically onto nitrocellulose membrane. Subsequently, the membranes were blocked with 5% skim milk and incubated overnight at 4 °C with primary antibody: anti-HO-1 (sc-10789, Santa Cruz Biotechnology, 1:300), anti-GCLC (ab-80841, abcam Biotechnology, 1:600), anti-GADPH (sc-47724, Santa Cruz Biotechnology, 1:1000), anti-*β*-actin (AP0060, Bioworld Technology, 1:3000). After being washed three times with 1× TBST, the membrane was incubated with anti-rabbit IgG for 1 h at room temperature. Proteins were visualized by exposure in a ChemiDoc XRS+system (Bio-Rad, Hercules, CA, USA). Band density was quantified by Image J software (National Institute of Health, Bethesda, MD, USA).

### 5.2.9. Materials and animals {#s0115}

2,3,5-Triphenyltetrazolium (TTC) was purchased from Sigma (St. Louis, MO, USA). Chloral hydrate was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). **33** and edaravone (ED) was dissolved in a solvent (Cremophor:PBS at 3:97) for the intraperitoneal injection. **33**/**21**/**1b**-nanoparticles were prepared for the intracerebroventricular injection. The **33**/**21**/**1b**-loaded nanoparticles were prepared as described previously[@bib93]. All animals were obtained from the Shanghai Slaccas Lab Animal Co., Ltd. All animal experiments and care were performed according to the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington D.C., USA, 1996). Animals were fed with a standard laboratory diet, and were housed in a temperature-controlled room (24 °C) and illuminated for 12 h daily (lights on from 5 a.m. to 5 p.m.).

### 5.2.10. BCAO-induced cerebral ischemia/reperfusion injury in mice {#s0120}

This ischemia/reperfusion model was carried out as described by Himori et al.[@bib94] with slight modifications. Briefly, male 8-week-old C57BL/6 mice were anaesthetized using 4% of chloral hydrate (0.1 mL/10 g; i.p.). A midline incision was made in the neck and the left and right carotid arteries were exposed. A loose silk ligature for occlusion (ischemia) was placed around both carotid arteries. Occlusion was maintained for 20 min, and this was followed by reperfusion for 24 h. In sham-operated animals, the arteries were exposed but not occluded. All mice were injected intraperitoneally 3 or 6 h after bilateral common carotid artery occlusion (BCAO).

### 5.2.11. Spontaneous locomotor activity test {#s0125}

After 24 h of reperfusion, the animals were placed in an open square chamber (40 cm^3^ box) equipped with horizontal and vertical infrared photo beams. Then, its behaviors were recorded for 5 min using the Digbehv software (DigBehav, Jiliang Co., Ltd., Shanghai, China). The locomotor activity was evaluated by measuring the total distance traveled in the apparatus.

### 5.2.12. MCAO-induced transient focal cerebral ischemia in rats {#s0130}

Male Sprague---Dawley rats (250--280 g) were used in this study. Rats have no interference factors such as infection and inflammation, and were used as the object of middle cerebral artery occlusion (MCAO) method. Firstly, rats were anesthetized with 10% of chloral hydrate (0.33--0.35 mL/100 kg; i.p.), and then placed them in the supine position. Secondly, after disinfection with iodine, the skin was cut. The common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA) were separated. Thirdly, the CCA and the ECA was ligated while the ICA was closed with an artery clamp temporarily. Then tiny incisions were made at the distance of 4 mm from the branch of CCA. The MCAO model was established by inserting thread through CCA into the anterior cerebral artery. The sham-operated group was treated with the same operation without ischemia-reperfusion.

### 5.2.13. Neurological deficit score and TTC staining {#s0135}

Neurological score was assessed 24 or 72 h after MCAO in rats. Five types of motor neurological findings are as follows. 0: no obvious deficit; 1: difficult to extend the lateral forelimb fully; 2: cannot extend the lateral forelimbs; 3: circling to the contralateral side; 4: difficult or impossible to move or roll spontaneously. TTC staining was performed to determine the infarct area. Firstly, the brain of the rat was taken out in time and placed in the refrigerator at --20 °C for 20 min. Secondly, the brain was cut into five slices with 2 mm thickness and placed in TTC staining (Sigma---Aldrich, USA) at 37 °C for 30 min. The TTC-stained brain slices were taken pictures with the camera, and then the Image-Pro plus was used to handle the infarct area.

### 5.2.14. Statistical analysis {#s0140}

Data were presented as means±SEM. The statistical differences between groups were determined by the Student׳s *t*-test or one-way analysis of variance for multiple comparisons in GraphPad Pro (GraphPad, San Diego, CA, USA). Differences were considered to be significant at *P*\<0.05.

Appendix A. Supplementary material {#s0155}
==================================
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